Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CTSH | P09668 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30566367 | 0.88 | CXCR4 (0.59) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL29833824 | 0.88 | CXCR4 (0.52) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL29845416 | 0.87 | KISS1R (0.57) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL29845535 | 0.86 | CXCR4 (0.60) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL30381291 | 0.86 | KISS1R (0.56) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL30307184 | 0.86 | CXCR4 (0.56) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL29833907 | 0.85 | CXCR4 (0.61) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL29500468 | 0.85 | C5AR1 (0.59) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL30566365 | 0.85 | CXCR4 (0.58) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL31187042 | 0.85 | CXCR4 (0.63) | CXCR4TACR1KISS1RIL23RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642898-A1 | GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF | AffyXell Therapeutics Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| CN-119213021-A | Stefin A protein variants that specifically bind to CD40L and uses thereof | 艾菲赛尔治疗株式会社 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024141790-A1 | GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF | AFFYXELL THERAPEUTICS CO., LTD. (KR) | 2024-07-04 | — | — | WO | disclosed |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| US-20230381330-A1 | ENZYME-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| CN-117042808-A | FAP activated serum half-life extending therapeutic conjugates | 阿瓦克塔生命科学有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116963781-A | Enzyme activated serum half-life extending therapeutic conjugates | 阿瓦克塔生命科学有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4237012-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Avacta Life Sciences Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| EP-4237011-A1 | ENZYME ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Avacta Life Sciences Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-20230272011-A1 | SERUM ALBUMIN-BINDING POLYPEPTIDES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| WO-2023153876-A1 | STEFIN A PROTEIN VARIANTS SPECIFICALLY BINDING TO CD40L, AND USES THEREOF | 주식회사 아피셀테라퓨틱스 | 2023-08-17 | — | — | WO | disclosed |
| CN-116419926-A | Serum albumin binding polypeptides | 阿瓦克塔生命科学有限公司 | 2023-07-11 | — | — | CN | disclosed |
| EP-4188957-A1 | SERUM ALBUMIN-BINDING POLYPEPTIDES | Avacta Life Sciences Limited (GB) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022234003-A1 | CD33 BINDING POLYPEPTIDES WITH STEFIN A PROTEIN | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022094237-A1 | ENZYME ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094262-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381330-A1 | ENZYME-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | DNPEP, ENGASE, ENPEP | CTSL 10/4885CTSS 39/4885CTSK 53/4885 |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | FAP, FIBP, FUCA2 | CTSL 21/4885CTSS 135/4885CTSK 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.